Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Pembrolizumab (Keytruda) for advanced or metastatic urothelial cancer – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Urothelial cancer is the most common form of bladder cancer, which usually starts in the bladder lining. Treatment of urothelial cancer is often successful at first, but the cancer may return and can spread to other parts of the body.
Pembrolizumab is a new drug for the treatment of urothelial cancer. It is delivered straight into the blood once every three weeks using a drip. Some studies have suggested pembrolizumab may be helpful for people who have advanced urothelial cancer after their first treatment has stopped working.
If pembrolizumab is licensed for use in the UK, it could be a new treatment option for patients with advanced urothelial cancer which may improve survival when current treatments have not worked. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Neoplasms; Neoplasms, Second Primary; Urothelium Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000404 Date abstract record published 04/03/2016 |